Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
grade F 101.13 2.38% 2.35
GLPG closed up 2.38 percent on Monday, March 18, 2019, on 74 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical GLPG trend table...

Date Alert Name Type % Chg
Mar 18 50 DMA Resistance Bearish 0.00%
Mar 18 Crossed Above 20 DMA Bullish 0.00%
Mar 18 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 18 Bollinger Band Squeeze Range Contraction 0.00%
Mar 18 Multiple of Ten Bullish Other 0.00%
Mar 18 BB Squeeze Started Range Contraction 0.00%
Mar 18 Gapped Up Strength 0.00%
Mar 15 20 DMA Resistance Bearish 2.38%
Mar 14 20 DMA Resistance Bearish 1.61%
Mar 14 NR7 Range Contraction 1.61%

Older signals for GLPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Medicine Medical Specialties Immunology Monoclonal Antibodies Autoimmune Diseases Inflammation Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Osteoarthritis Inflammatory Diseases Ulcerative Colitis Arthritis Abdominal Pain Colitis Treatment Of Inflammatory Diseases Treatment Of Inflammation
Is GLPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 122.28
52 Week Low 85.0
Average Volume 82,265
200-Day Moving Average 102.4357
50-Day Moving Average 101.239
20-Day Moving Average 99.394
10-Day Moving Average 99.181
Average True Range 2.1512
ADX 12.58
+DI 27.8196
-DI 27.635
Chandelier Exit (Long, 3 ATRs ) 97.4464
Chandelier Exit (Short, 3 ATRs ) 102.66359999999999
Upper Bollinger Band 102.8125
Lower Bollinger Band 95.9755
Percent B (%b) 0.75
BandWidth 6.878685
MACD Line -0.3433
MACD Signal Line -0.4796
MACD Histogram 0.1363
Fundamentals Value
Market Cap 5.14 Billion
Num Shares 50.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -144.47
Price-to-Sales 23.11
Price-to-Book 3.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 103.52
Resistance 3 (R3) 103.32 102.34 103.12
Resistance 2 (R2) 102.34 101.73 102.43 102.98
Resistance 1 (R1) 101.73 101.35 102.04 101.93 102.85
Pivot Point 100.75 100.75 100.90 100.84 100.75
Support 1 (S1) 100.14 100.14 100.45 100.34 99.41
Support 2 (S2) 99.16 99.76 99.25 99.28
Support 3 (S3) 98.55 99.16 99.14
Support 4 (S4) 98.75